 |
Solebury Trout is working with the investment community for Novavax, which has announced its COVID-19 vaccine has a 93 percent efficacy rate against the virus.
Stanley Erck, CEO of the Gaithersburg, MD biotech, said Novavax “is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines."
The firm plans to file for regulatory approval for its NVX-CoV2373 vaccine in the third quarter.
Once approved, Novavax said it will be able to produce 100M shots a month by the end of Q3 and 150 doses by year-end.
Novavax, which is 33 years old, has never had a vaccine approved by the Food and Drug Administration.
Solebury Trout’s Alexandria Roy represents Novavax.
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
Uber’s Mike Lucarelli is moving to NXP Semiconductors as senior VP-investor relations.
